ACTRN12619001052123招募中2 期
A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Male or females between the ages of 18 and 75 years
- •- Clinical diagnosis of essential tremor (ET)
- •- Stable dose of 1 tremor medication throughout the clinical trial, or no other tremor medications
排除标准
- •- Clinical evidence of psychogenic tremor
- •- History of other medical, neurological or psychiatric condition that may explain or
- •cause tremor
- •- Prior magnetic resonance-guided focused ultrasound or surgical intervention for ET
- •such as deep brain stimulation or thalamotomy
- •- Botulinum toxin injection for ET in the 6 months prior to Screening
- •- Unwilling or unable to discontinue primidone
- •- Unwilling or unable to refrain from alcohol 24 hours before and during the clinical trial
- •- Any other significant disease, disorder or lab abnormalities that may either put the patient at risk due to participation in the clinical trial, may influence or confound the result of the clinical trial, or affect the patient’s ability to participate in the clinical trial.
研究者
相似试验
招募中
2 期
A Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Essential Tremor - Part BACTRN12622000408785Praxis Precision Medicines12
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2, 4, 5 and 6MedDRA version: 16.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 16.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-GBMerck Sharp & Dohme Corp.100
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-ESRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-GBRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
Clinical Trial testing the combination of MK-5172 with/without MK-8742 and/or Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2/4/5/6MedDRA version: 17.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,100